Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

被引：23

作者：

Gallant, Joel E. ^{[1
]}

Koenig, Ellen ^{[2
]}

Andrade-Villanueva, Jaime F. ^{[3
]}

Chetchotisakd, Ploenchan ^{[4
]}

DeJesus, Edwin ^{[5
]}

Antunes, Francisco ^{[6
]}

Arasteh, Keikawus ^{[7
]}

Rizzardini, Giuliano ^{[8
]}

Fehr, Jan ^{[9
]}

Liu, Hui C. ^{[10
]}

Abram, Michael E. ^{[10
]}

Cao, Huyen ^{[10
]}

Szwarcberg, Javier ^{[10
]}

机构：

[1] Southwest CARE Ctr, Santa Fe, NM USA

[2] Inst Dominicano Estudios Virolog, Santo Domingo, Dominican Rep

[3] Hosp Civil Guadalajara, HIV Unit, Guadalajara, Jalisco, Mexico

[4] Khonkaen Univ, Dept Med, Khon Kaen, Thailand

[5] Orlando Immunol Ctr, Orlando, FL USA

[6] Fac Med Lisbon, Inst Saude Ambiental, Lisbon, Portugal

[7] Vivantes Auguste Viktoria Klinikum, EPIMED, Berlin, Germany

[8] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy

[9] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland

[10] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2015年 / 69卷 / 03期

关键词：

Cobicistat; pharmacoenhancer; HIV; Antiretroviral; clinical trial; INITIAL TREATMENT; TREATMENT-NAIVE; DOUBLE-BLIND; LOPINAVIR/RITONAVIR; PHARMACOKINETICS; INFECTION; GS-9350; REGIMEN;

D O I：

10.1097/QAI.0000000000000598

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background:Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.Methods:International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.Results:At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.Conclusions:Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

引用

页码：338 / 340

页数：3

共 50 条

[1] Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results
Gallant, Joel E.
Koenig, Ellen
Andrade-Villanueva, Jaime
Chetchotisakd, Ploenchan
DeJesus, Edwin
Antunes, Francisco
Arasteh, Keikawus
Moyle, Graeme
Rizzardini, Giuliano
Fehr, Jan
Liu, Yapei
Zhong, Lijie
Callebaut, Christian
Szwarcberg, Javier
Rhee, Martin S.
Cheng, Andrew K.
JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (01): : 32 - 39
[2] Cobicistat versus ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir disoproxil fumarate/emtricitabine: phase 3 randomized, double blind, active-controlled trial, week 48 results
Gallant, J.
Koenig, E.
Andrade-Villanueva, J.
Chetchotisakd, P.
Dejesus, E.
Antunes, F.
Arasteh, K.
Moyle, G.
Rizzardini, G.
Fehr, J.
Liu, Y-P.
Zhong, L.
Callebaut, C.
Ramanathan, S.
Szwarcberg, J.
Rhee, M.
Cheng, A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 53 - 53
[3] Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort
Perrier, Marine
Charpentier, Charlotte
Peytavin, Gilles
Le, Minh
Blondel, Louis
Visseaux, Benoit
Joly, Veronique
Pinto, Adriana
Matheron, Sophie
Yazdanpanah, Yazdan
Descamps, Diane
Landman, Roland
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (06) : 1745 - 1751
[4] Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
Kulkarni, Rima
Abram, Michael E.
McColl, Damian J.
Barnes, Tiffany
Fordyce, Marshall W.
Szwarcberg, Javier
Cheng, Andrew K.
Miller, Michael D.
White, Kirsten L.
HIV CLINICAL TRIALS, 2014, 15 (05): : 218 - 229
[5] Elvitegravir/emtricitabine/tenofovir-disoproxil-fumarate/cobicistat/emtricitabine/tenofovir-disoproxil-fumarateCluster headache: case report
Reactions Weekly, 2024, 2033 (1) : 105 - 105
[6] Atazanavir/emtricitabine/tenofovir disoproxil fumarate interactionDecreased atazanavir plasma concentration: case report
Reactions Weekly, 2013, 1471 (1) : 11 - 11
[7] Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients
Biagi, M.
Badowski, M. E.
Chiampas, T.
Young, J.
Patel, M.
Vaughn, P.
INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 766 - 772
[8] Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients
Orkin, C.
Clumeck, N.
Girard, P-M
Henry, K.
Gathe, J.
Rockstroh, J.
DeJesus, E.
Yau, S.
Smith, A.
Wei, X.
White, K.
Fordyce, M.
Rhee, M.
Szwarcberg, J.
HIV MEDICINE, 2014, 15 : 114 - 114
[9] A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
Zolopa, Andrew
Sax, Paul E.
DeJesus, Edwin
Mills, Anthony
Cohen, Calvin
Wohl, David
Gallant, Joel E.
Liu, Hui C.
Plummer, Andrew
White, Kirsten L.
Cheng, Andrew K.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (01) : 96 - 100
[10] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
Ramanathan, Srini
Custodio, Joseph M.
Wei, Xuelian
Wang, Hui
Fordyce, Marshall
Dave, Ami
Ling, Kah Hiing J.
Szwarcberg, Javier
Kearney, Brian P.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288

← 1 2 3 4 5 →